Introduction
Despite the increasing use of molecular characterization of mutations in the prognostic risk classification of acute myeloid leukemia (AML), conventional cytogenetic studies at diagnosis remain a highly influential risk factor. The presence of a complex karyotype (CK+) 1, 2 or monosomy of either chromosome 5 3 or chromosome 7 4 has been universally associated with unfavorable prognosis. Recently the UK MRC added monosomy 17 to its list of independent predictors of poor outcome with their refinement of the AML cytogenetic classification categories. 5 Although there has been no change in induction therapy for nearly 4 decades 6 , subgroups that respond particularly well or poorly have been identified based on their genetic features. 1, 4, 5, [7] [8] [9] Careful examination of disease characteristics at diagnosis is imperative to identify high-risk patients and to appropriately apply risk-adapted molecularly targeted therapies or intensified treatment strategies including hematopoietic stem cell transplantation (HSCT).
The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer
Research (HOVON/SAKK) group was the first to demonstrate the potential of monosomal karyotypes (MK) to delineate a subgroup with very poor risk and thus refined the cytogenetic classification of AML patients < 60 years. 8 MK+ was defined as either the presence of two or more autosomal monosomies or one monosomy plus at least one structural abnormality and was associated with a 4% 4-year overall survival (OS) compared to 26% for MK-patients. Particularly unfavorable outcomes in MK+ patients > 60 years were reported by the Southwest Oncology Group (SWOG) with a 4-year OS of 1% and less than one third of MK+ patients between ages 31 to 60 years achieved complete remission (CR). 10 Haferlach and colleagues in the Munich Leukemia Laboratory Group reported that complex karyotype defined as ≥4 unrelated abnormalities identified the largest proportion of very poor risk AML patients and suggested that the combination of CK≥4 and MK+ status would be the most sensitive metric in identifying those with unfavorable prognosis. 11 Additionally, degree of cytogenetic complexity has been shown to identify the subgroups of MDS patients with the worst prognosis, independent of MK+ status. 12, 13 In fact, when accounting for karyotype complexity MK was not an independent prognostic factor in patients with myelodysplastic syndrome. 12, 13 Whether the prognostic value of specific monosomies such as monosomy 5, monosomy 7, or monosomy 17 is preserved in the context of MK+ AML is uncertain. Therefore, we conducted a retrospective analysis of AML patients enrolled in four Eastern Cooperative Oncology Group and the American College of
Radiology Imaging Network Cancer Research Group (ECOG-ACRIN) therapeutic clinical trials between 1990
and 2008 to determine whether individual monosomies, karyotype complexity, age, or baseline disease characteristics impact outcome in MK+ disease.
Methods

Patients
Eligible patients for this study were defined as previously untreated AML patients enrolled in one of four prospective ECOG-ACRIN therapeutic clinical trials (E1490, E1900, E3993, and E3999) between 1990 and 2008. [14] [15] [16] [17] Newly diagnosed AML patients (excluding acute promyelocytic leukemia) were eligible for enrollment onto the therapeutic protocols. Except for those enrolled onto E1900, patients were required to be at least 55 years of age. All patients received induction chemotherapy containing cytarabine combined with daunorubicin, idarubicin, or mitoxantrone +/-additional investigational agents as defined by the respective protocol. Postremission therapeutic strategies were defined per individual protocol and not influenced by the identification of MK+ disease. All patients signed informed consent prior to enrollment. The studies were approved by ethics committees of all participating institutions and conducted in accordance with the Declaration of Helsinki. A total of 1,592 AML patients ranging 17-93 years of age were enrolled on the aforementioned trials.
Evaluable cytogenetics data are available on 1,188 patients included in this analysis. Patients enrolled on E1900 accounted for the largest number of the 1,188 patients (45%; 535), followed by those on E3999 (29%; 345), E3993 (22%; 266), and E1490 (4%; 42).
Cytogenetic evaluation
Diagnostic bone marrow aspirate or heparinized peripheral blood was examined for cytogenetic abnormalities by unstimulated standard culturing and banding techniques by individual institutional or referral cytogenetic laboratories. Results and karyotypes were centrally reviewed by the ECOG-ACRIN Cytogenetics Committee and designated in accordance with the International System for Human Cytogenetic Nomenclature (ISCN).
Karyotypic analysis was based on minimum review of 10 available metaphases. Normal karyotype required a minimum of 20 normal diploid metaphases. Abnormalities were considered clonal when at least 2 metaphases had the same structural abnormality or the same trisomy or when at least 3 metaphases displayed the same monosomy. Structural abnormalities were defined as deletions, translocations, inversions, and additions for the purposes of this study and in accordance with the definition used by HOVON/SAKK 8 
Statistical Analysis
Patient baseline characteristics were compared using Fisher's exact test if they were categorical and Wilcoxon rank sum tests if they were continuous. OS was defined as time from study randomization/registration to death from any cause, with follow-up censored at the date of last contact. Kaplan-Meier estimates were used to estimate the event-time distributions for OS. Log-rank tests stratified on studies and induction treatments were used to examine the effects of MK or other chromosomal abnormalities on OS. Multivariate Cox model stratified on studies and induction treatments was performed on OS to examine the prognostic effect of MK or other chromosomal abnormalities while controlling for potential risk factors {Multivariate analysis included the factors of MK+ status, karyotype complexity, gender, age, WBC count, hemoglobin, platelet count, marrow and blood blast %, secondary vs de novo AML, and the occurrence of independent high-risk cytogenetic abnormalities [del5q, del7q, del17p, inv3, t(6;9), 11q23, and t(9;22)] where appropriate}. All P values were based on 2-sided tests.
Results
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Cytogenetic Abnormalities
Cytogenetics were evaluable in 1188 / 1592 (75%) of AML patients enrolled onto the four protocols. An overview of the frequency of normal as well as clonal cytogenetic abnormalities is seen in 
Baseline Characteristics
Significant differences were observed in age, WBC count, hemoglobin, platelet count, peripheral and bone marrow blast percentages at diagnosis and percentages of secondary AML between MK+ and MK-patients (Table 2) . MK+ patients tended to be older and have a lower presenting WBC count, lower percentage of circulating or bone marrow blasts, lower hemoglobin, and a lower platelet count at presentation. MK occurred in 7% (25 / 383) patients <55 years compared to 21% (170 / 805) patients ≥55 years (p<0.001).
Monosomies were detected for each chromosome at least once, but occurred least frequently with chromosomes 1, 2, 8, and 15. Monosomy 7 accounted for 53% (51/97) of the single monosomies and was present in 47% (107/229) of all patients in whom monosomies were identified. Monosomy 17 was the most frequent monosomy occurring in patients containing multiple monosomies (48%; 64/132), followed by monosomy 7 (42%; 56/132) and monosomy 5 (39%; 52/132) ( Table 3 ). Double monosomies of individual chromosomes were uncommon (12%; 16/132) and affected chromosomes 3, 5, 9, 12, 13, 14, 15, 16, 17, 18, 20 , and 21.
Prognostic Associations
Median follow-up of the patients included in this analysis was 5.2 years. CR rate amongst all 1,188 evaluable patients was 53.4%. Outcome measures based on MK+/-status of the 578 patients with non-CBF clonal abnormalities are reported in Table 4 . CR was achieved in 31% (61/195) of MK+ non-CBF patients compared to 47% (179/383) of MK-non-CBF patients with a 4-year OS of 3% and 14% (P<0.001), respectively. Among patients ≥ 55 years, CR occurred in 30% (51/170) of MK+ non-CBF patients compared to 42% (116/276) of MK-non-CBF patients and was associated with a 4-year OS of 1% versus 10%, respectively (p<0.001). MK+ non-CBF patients <55 years achieved CR at a rate of 40% (10/25) compared to 59% (63/107) in MK-non-CBF patients and was related to a 4-year OS of 16% versus 27%, respectively (p=0.02).
CR was achieved in 22% (14/63) of patients with a single monosomy and structural abnormalities compared to 33% (11/33) with an isolated monosomy (p=0.33, with 4-year OS of 5% and 9%, respectively Figure   1 ). When accounting for karyotype complexity among patients with at least one clonal abnormality, 22% MK+ patients with karyotype complexity ≤4 clonal abnormalities achieved CR compared to 47% of those non-CBF MK-AML and the same degree of complexity (p=0.003) ( Table 5 ). Median OS for MK+ patients with ≤4 clonal abnormalities was 0.3 years compared to 1.0 years for those that were MK-with non-CBF clonal abnormalities (p<0.001; HR: 1.98; 95%CI 1.40, 2.81) ( Figure 1A ). Of note, median OS was essentially unchanged when limiting the analysis to those MK+ patients with karyotype complexities of only 3 or 4 abnormalities (OS 0.3 years) compared their MK-counterparts (1.1 years; p=0.039;)(Supplemental Figure 2) . MK+ status in patients with karyotype complexity ≤4 remained significant (p=0.01, HR 1.78; 95%CI 1.13, 2.79) by multivariate (Table   6) .
No difference was seen in CR (38% vs 34%; p=0.82; Table 5 ) or OS (median 0.5y vs 0.4y; p=0.82;) in patients with karyotype complexity ≥5 (CK≥5) and differing MK+/-status ( Figure 1B) . MK+ status also failed to demonstrate significance within the CK≥5 population (p=0.47) by multivariate (Table 6 ).
Monosomy 5
Monosomy 5 Table 1 ).
Monosomy 5 rarely occurred in patients with non-CBF clonal abnormalities with a karyotype complexity ≤4 (8%; 3/37), but its presence in this population appeared to be associated with a poor overall survival and a HR of 4.13 (95%CI 0.82, 20.8) (Figure 2A ) although the small number of occurrences (n=3) in this context precludes any definitive statement of significance.
Monosomy 7
Monosomy 7 (+/-monosomy 5 +/-monosomy 17) was identified in 107 patients and the majority (74%; 79/107) met the criteria for MK+ disease with 63% (59/79) also possessing CK≥5. CR rates were not different for monosomy 7 patients with or without MK+ (32% v. 33%) and were similar (30%) for MK+ patients lacking (Figure 2D ). Interestingly, multivariate analysis suggested improved survival among MK+ patients with monosomy 7 compared to those without monosomy 7 in both the CK≤4 (p=0.0005; HR: 0.03; 95%CI 0.004, 0.21) and CK≥5 cohorts (p=0.03; HR 0.62; 95%CI 0.40, 0.94) (Supplemental Table 2 ). Table 3 ).
Contribution of Concurrent Monosomy 5, 7, and/or 17
Outcomes of patients with monosomy 5 and/or monosomy 7 and/or monosomy 17 relative to MK+ status are presented in Table 4 . In the absence of monosomy 7 and monosomy 17, monosomy 5 occurred in 13 patients with non-CBF cytogenetic abnormalities with 12/13 being MK+ (CR 25%, 4yOS= 0%). In the absence of monosomy 5 and monosomy 17, monosomy 7 occurred in 74 patients with 28/74 being MK-(CR 32.1%, 4yOS=11%) and 46/74 being MK+ (CR 30.4%, 4yOS 7%; log-rank test for OS p=0.10). In the absence of monosomy 5 and monosomy 7, monosomy 17 occurred in 33 patients with all being MK+ (CR 36.4%, 4yOS = 0%). Of 172 patients possessing karyotypes with monosomy 5 and/or monosomy 7 and/or monosomy 17, only 4% (7/172) were known to be alive at 4 years and each were observed to possess monosomy 7.
Karyotypes Table 4 ).
Discussion
Through the collective analysis of the data and outcomes of 1,592 patients enrolled onto four prospective ECOG-ACRIN AML therapeutic trials, we now contribute a number of new observations relevant to the cytogenetic categories of MK+ and CK+ AML. Monosomy 5 appeared to have no independent prognostic value and the negative prognostic value of monosomy 7 was lost in the context of MK+ AML. Additionally, the prognostic value of the MK+ designation appeared to be restricted to those patients with karyotype complexity ≤4 clonal abnormalities. However, monosomy 17 was found to occur exclusively within monosomal karyotype patients and to independently predict for worse survival among MK+ patients as well as those with highly complex karyotypes (MK+/CK≥5).
Poor prognosis associated with chromosomal aberrations involving the long arm of chromosomes 5 or 7 [add/del (5q) or add/del (7q)] as well as complete loss of chromosome 5 or 7 (monosomy 5 or monosomy 7)
has been previously described. 1, 5 Our data demonstrate that monosomy 5 occurred almost exclusively in the setting of MK+ (53/54) and highly complex (50/54 with CK≥5) karyotypes, and that monosomy 5 contributed no prognostic value within the CK≥5 patients. This data suggests that the negative impact previously attributed to monosomy 5 is actually attributable to karyotype complexity. Review of the HOVON/SAKK, SWOG, and
Groupe Ouest-Est d'Etude des Leucémies et Autres Maladies du Sang (GOELAMS) reports of their individual
monosomal karyotype experiences also failed to reveal a single case of monosomy 5 occurring outside of MK+ AML. 8, 10, 20 While these reports do not directly describe the frequency of monosomy 5 within their CK+ AML population, it should be noted that 89% (417/470) of the collective MK+ patients described by HOVON/SAKK, SWOG, GOELAMS carried the CK+ designation with CK+ defined as ≥ 3 clonal abnormalities in each analysis.
Although our data confirm that the prognosis for AML patients with monosomy 7 (in the absence of monosomal karyotype) is poor (Table 4) , it should be noted that the negative prognostic impact of monosomy 7 was lost in the context of MK+ AML (Figures 2C, 2D ; Supplemental Table 2 ). Although no difference in survival was seen by univariate analysis amongst MK+ / CK≥5+ / Monosomy 7+ patients compared to those without monosomy 7 ( Figure 1D ), the presence of monosomy 7 was actually observed to confer a statistically significant improvement in survival for MK+ patients regardless of karyotype complexity ≤4 or ≥5; Supplemental Table 2 ).
While the poor prognostic impact of 17p aberrations 21, 22 and the collective group of chromosome 17 abnormalities 23, 24 in AML have been demonstrated, the significance of monosomy 17 itself has not been well The strong association between monosomies and their occurrence in complex karyotypes illustrates the significant shortcomings of the current ISCN nomenclature when defining a "monosomy". Nearly all complex karyotypes with apparent monosomies have multiple concurrent unclassifiable portions of chromosomal material, i.e., "add" chromosomes, marker chromosomes or ring chromosomes, which likely represent portions of the missing monosomies listed in the ISCN. In should also be noted that, the identification of double monosomies (loss of both copies of the same chromosome) is always accompanied by structural abnormalities, presumably representing critical portions of one of the missing chromosomes since true double monosomy is not compatible with cell viability. Thus, evaluating the whole genome of leukemia cells via the emerging technologies of whole genome microarrays and next generation sequencing techniques 25 will provide more accurate characterization as to the extent of true chromosomal gains and losses associated with complex karyotypes with apparent monosomies.
Although numerous reports have demonstrated the association of dismal outcomes with AML patients of advanced age and the increased incidence of high-risk cytogenetic abnormalities among this population [26] [27] [28] , it should not be assumed that the prognostic impact of MK is simply a reflection of the advanced age of the population in which is more commonly occurs. The data reported by HOVON/SAKK, SWOG, and GOELAMS has consistently demonstrated inferior outcomes among MK+ AML patients compared to their age-matched MK-counterparts. 8, 10, 20 While the ECOG-ACRIN experience reported here also demonstrated an increased incidence of MK+ among older patients (≥55y) compared to their younger counterparts, the prognostic significance of MK+ occurring within less complex karyotypes (≤4 clonal abnormalities) was retained when controlling for age via multivariate analysis (Table 6 ). It should also be noted that the prognostic significance of monosomy 17 (occurring exclusively within the MK+ population) was also retained when controlling for age by multivariate analysis regardless of karyotype complexity (Supplemental Table 3 ). Our data further support the delineation of the risk group characterized by the presence of MK+ with subgroups possessing similar median OS regardless of karyotype complexity (Supplemental Figure 1) . Median OS of CK+/MK-disease was twice that of CK+/MK+ patients and was best among those with CK-/MK-AML.
The ECOG-ACRIN experience demonstrates that CK≥5 and MK+ (with karyotype complexity ≤4) designations reliably predict poor outcomes for which no consistently effective therapeutic strategy has yet been identified. Allogeneic HSCT and possibly the incorporation of high-dose cytarabine 29 into a patient's therapeutic regimen may improve outcomes. However, the benefit of these treatments appears marginal and advanced age and resultant comorbidities limit the feasibility of these therapies for many CK≥5 and MK+ patients. While allogeneic HSCT appears to be the only potentially curative option available, overall outcomes remain poor with HSCT of MK+ patients yielding a 4-year OS of 25% compared to 0% without transplant as reported by the Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance. 30 Similarly, the Center for International Blood and Marrow Transplant Research has reported a 3-year OS of 29% and that MK+ AML patients was associated with higher mortality (p<0.001; RR 1.67; 95%CI 1.38, 2.01) than that of 13 normal karyotype AML patients undergoing HSCT. 31 32 Although AML is often treated uniformly, it is increasingly evident that this disease is largely heterogeneous with genetically distinct subgroups. The possibility exists that prior lack of awareness of disease subgroups, such as MK+ disease, has negatively impacted outcomes and inhibited the advancement of therapeutic options for better risk subgroups. Inclusion of the MK+ patient population and its dismal prognosis on clinical trials along with relatively better risk AML patients may obscure the recognition of therapeutic benefits for patients with better risk disease. Accounting for these subgroups via mechanisms such as the hierarchical classification according to specific chromosomal lesions as proposed by Middeke et al 22 may enable more appropriate selection of patients for particular therapeutic modalities such as allogeneic HSCT. They describe the ability to select MK+ patients with better HSCT outcomes based on the presence or absence of abnl(17p) or monosomy 5 / del(5q) lesions. Given the association of TP53 abnormalities with MK+ AML 33 , the authors allude to the possibility that TP53 abnormalities may play a role in resistance of this MK+ subset against the graft-versus-leukemia effect of allogeneic HSCT. 22 Of note, TP53 mutation status was known on six of the monosomy 17 patients included in our analysis and, interestingly, none of these six were found to possess TP53 mutations. As such, the true degree to which TP53 abnormalities or possible aberrations associated with the loss of genes on 17q such as ERBB2, NF1, RARA, BRCA1, or STAT3 contribute to resistance within monosomy 17 patients is unknown and warrants further investigation.
With the potential promise of molecular targeting it is imperative that we decipher the pathophysiologic mechanisms associated with the poor outcome of MK+ AML patients. Thoughtful design of future AML clinical trials, accurate identification of a patient's cytogenetic/molecular risk profile prior to trial enrollment, and investigation of more homogenous AML subgroups may open the door to therapeutic advances and improved outcomes that have been lacking in this disease. The feasibility of such an approach is currently under investigation [NCT01684150] based on the discovery that DOT1L inhibition is able to induce selective cytotoxicity in poor risk MLL-rearranged leukemic cells while sparing non-rearranged cells. 34, 35 Similarly, the prevalence of TP53 alterations within CK+ AML 33 makes p53 a potentially attractive target to explore in this population. Although targeting p53 has presented significant challenges in the past, agents are now available which restore wild-type activity to mutant p53 proteins (APR-246 36, 37 ) and agents which disrupt MDM/p53 interactions (RG7112 38, 39 , JNJ-26854165 40 ) and subsequently lead to apoptosis. 41 In conclusion, while MK is an independent predictor of outcomes in adult AML patients, our data suggest the prognostic utility of the MK+ designation appeared to be limited to those with less complex karyotypes (complexity ≤4). Our study draws into question the independent prognostic value of monosomy 5 as this monosomy occurred almost exclusively in MK+ and CK≥5 patients. The majority of monosomy 7 occurrences appeared in the context of MK+ disease where its prognostic value was lost regardless of karyotype complexity. Although the independent significance of monosomy 5 and monosomy 7 were lacking within the context of MK+ AML, monosomy 17 defined a distinct subcategory of MK+ AML. The very poor prognosis associated with MK+/CK≤4 AML, monosomy 17+ AML, and highly complex (CK≥5) AML underscores the need for better understanding of the genetic aberrations and potential targets present within these karyotypes to guide investigation of novel therapeutic strategies in this group of patients. 
